Introduction {#H1-1-ZOI190207}
============

Postoperative atrial fibrillation (POAF) is a well-known complication of cardiac surgery, putting patients at an increased risk of morbidity and mortality. Epidemiological studies^[@zoi190207r1],[@zoi190207r2],[@zoi190207r3],[@zoi190207r4],[@zoi190207r5]^ showed that approximately one-third of patients develop atrial fibrillation (AF) after coronary artery bypass graft surgery (CABG), meaning that of the approximately 800 000 people who undergo CABG worldwide, more than 264 000 will develop post-CABG AF. Large-sample data analysis also showed that men had a significantly higher risk of POAF.^[@zoi190207r1],[@zoi190207r2],[@zoi190207r3],[@zoi190207r4],[@zoi190207r5]^

POAF is also costly in terms of medical resources owing to the prolonged duration of hospitalization.^[@zoi190207r6],[@zoi190207r7]^ Results from a 2014 large-sample study^[@zoi190207r8]^ showed that POAF is strongly associated with long-term development of AF after cardiac surgery.

Advanced age, history of AF, metabolic syndrome, and cardiac and renal dysfunction have been found to be potential risk factors for POAF, but the underlying mechanisms of POAF remain elusive.^[@zoi190207r9]^ Research^[@zoi190207r9]^ has suggested that inflammation, dysregulation of the autonomic nervous system, and overactivation of the renin-angiotensin system (RAS) system are involved in the pathogenesis of POAF.

Previous data^[@zoi190207r10],[@zoi190207r11]^ have shown that use of RAS inhibitors (RASIs), that is, upstream therapy, was associated with reduced risk of AF in selected populations because of their organ protection, remodeling prevention, and anti-inflammation effects. However, the existing consensus is mainly derived from nonsurgical populations, and the role of preoperative RASI therapy among patients in the surgical setting remains unclear.^[@zoi190207r12]^ In this study, we aim to evaluate the role of preoperative use of RASIs for the prevention of POAF in patients undergoing cardiac surgery by conducting a collaborative systematic review and meta-analysis of the most updated clinical studies.

Methods {#H1-2-ZOI190207}
=======

This study was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses ([PRISMA](http://www.equator-network.org/reporting-guidelines/prisma/)) reporting guideline for conducting a systematic review and meta-analysis.^[@zoi190207r13]^ Each individual study included in the systematic review was approved by their own institutional ethics committee, and the informed consent was obtained by each individual study.

Search Strategies {#H2-1-ZOI190207}
-----------------

We identified clinical trials that compared the preoperative use of RASIs (treatment group) with no RASIs (control group) in patients undergoing cardiac surgery. An online search of the published literature was performed using the PubMed database and the Cochrane Library from inception until December 31, 2018. The search was developed by using keywords *renin-angiotensin system inhibitors* OR *angiotensin-converting enzyme inhibitors* OR *angiotensin receptor blocker* OR *aldosterone antagonist* AND *cardiac surgery*. An additional search was performed in the ClinicalTrials.gov website from inception until December 31, 2018, using keywords *postoperative atrial fibrillation*.

Selection Criteria and Study Outcomes {#H2-2-ZOI190207}
-------------------------------------

Randomized and observational studies were included in the initial search. The treatment group comprised patients treated with RASIs, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or aldosterone antagonists, whereas the control group comprised patients who did not receive any RASIs. The study population consisted of patients undergoing CABG or cardiac valvular surgery. The primary outcome was rate of POAF, the identification of which was based on 12-lead electrocardiographic monitoring during the study period. The rates of stroke and mortality and duration of hospitalization were analyzed as secondary outcomes. The selection criteria were predefined, and the search process was conducted by 2 investigators (S.C. and M.G.K.). Discrepancies were resolved by discussions.

Data Extraction and Quality Assessment {#H2-3-ZOI190207}
--------------------------------------

Data extraction and presentation followed the recommendations of the PRISMA statement.^[@zoi190207r13]^ The data extracted included study characteristics, patient characteristics, treatment, and outcome data. We assessed the methodological quality of the included studies based on the recommendation of the PRISMA statement^[@zoi190207r13]^ and the *Cochrane Handbook for Systematic Reviews of Interventions*.^[@zoi190207r14]^ The key items were summarized by using the following queries: (1) randomized study? (2) double-blinded? (3) clear definition of study population? (4) clear definition of study comparison? (5) clear definition of outcome assessment? (6) appropriate statistical method used? (7) no selective loss of data analysis? and (8) important confounders identified? Each yes response scored 1 point, and a study assessed with 6 points or more was considered high quality. Discrepancy regarding study quality was resolved by consensus.

Statistical Analysis {#H2-4-ZOI190207}
--------------------

The statistical analyses were performed following the recommendations of the *Cochrane Handbook for Systematic Reviews of Interventions.*^[@zoi190207r14]^ The categorical variables were reported as percentages and estimated using a Mantel-Haenszel odds ratio (OR) with a 2-tailed 95% CI, whereas continuous variables were analyzed by weighted mean difference. The *I*^2^ statistic assessed by *Q* test was used to quantify the degree of between-study heterogeneity. Given the intrinsic variations in study design, we calculated the OR or the weighted mean difference estimates using random-effects models for all comparisons. Overall effect of primary outcome was tested by sensitivity analysis.

Publication bias was assessed using the Begg adjusted rank correlation test and the Egger regression asymmetry test.^[@zoi190207r14]^ To explore the effect of covariates on the overall treatment effect, we performed a random-effects meta-regression analysis, wherein the logarithm of the OR for primary outcome was regressed against the baseline characteristics of the included studies. All *P* values were 2 tailed, and the statistical significance was set at *P* \< .05. Statistical analyses were performed using the Revman software, version 5.3 (The Cochrane Collaboration); Stata software, version 12.0 (StataCorp); and Comprehensive Meta-Analysis Software, version 2.2 (Biostat, Inc).

Results {#H1-3-ZOI190207}
=======

Baseline Characteristics {#H2-5-ZOI190207}
------------------------

As shown in eFigure 1 in the [Supplement](#note-ZOI190207-1-s){ref-type="supplementary-material"}, the search strategy retrieved a total of 2045 citations. Of these, 1758 reports were excluded based on titles, abstracts, and article types. The remaining 287 full-text articles were screened further for eligibility, and 276 were excluded through predefined inclusion criteria. Consequently, 11 unique studies characterizing a total of 27 885 unique patients (median age, 65 years \[range, 58.5-74.5 years\]; 74.4% male and 25.6% female) were selected into our meta-analysis.^[@zoi190207r15],[@zoi190207r16],[@zoi190207r17],[@zoi190207r18],[@zoi190207r19],[@zoi190207r20],[@zoi190207r21],[@zoi190207r22],[@zoi190207r23],[@zoi190207r24],[@zoi190207r25]^ The baseline characteristics of included studies are summarized in [Table 1](#zoi190207t1){ref-type="table"}, and quality assessment for included trials is presented in eTable 1 in the [Supplement](#note-ZOI190207-1-s){ref-type="supplementary-material"}. Outcome data of included studies were extracted and are detailed in eTable 2 in the [Supplement](#note-ZOI190207-1-s){ref-type="supplementary-material"}. eTable 3 in the [Supplement](#note-ZOI190207-1-s){ref-type="supplementary-material"} summarizes the use of RASIs in individual studies. eTable 4 in the [Supplement](#note-ZOI190207-1-s){ref-type="supplementary-material"} shows the perioperative use of antiarrhythmic drugs.

###### Baseline Characteristics of Individual Studies

  Source                                   Study Design   Study Setting   Intervention of Interest   Sample Size, RASI/Control Groups, No. of Participants   Mean Age, RASI/Control Groups, y   Male sex, RASI/Control Groups, %   Prior AF, RASI/Control Groups, %   EH, RASI/Control Groups, %   Diabetes, RASI/Control Groups, %   Prior MI, RASI/Control Groups, %   Use of β-Blockers, RASI/Control Groups, %   Use of Statins, RASI/Control Groups, %   CHF, RASI/Control Groups, %   Length of Follow-up
  ---------------------------------------- -------------- --------------- -------------------------- ------------------------------------------------------- ---------------------------------- ---------------------------------- ---------------------------------- ---------------------------- ---------------------------------- ---------------------------------- ------------------------------------------- ---------------------------------------- ----------------------------- ---------------------
  White et al,^[@zoi190207r15]^ 2007       PC             CABG/VS         Preoperative RASIs         175/163                                                 65.4/65.9                          76.6/79.1                          4.0/3.1                            89.7/65.6                    45.7/22.7                          42.9/31.9                          82.3/85.9                                   76.0/60.1                                12.6/7.4                      30 d
  Ozaydin et al,^[@zoi190207r16]^ 2008     RCT            CABG/VS         Preoperative RASIs         98/30                                                   58.5/60.0                          55.1/70.0                          Excluded                           61.2/40.0                    39.8/36.7                          NA                                 88.8/96.7                                   NA                                       9.2/6.7                       In hospital
  Miceli et al,^[@zoi190207r17]^ 2009      RC             CABG            Preoperative ACEI          3052/3052                                               64.9/64.8                          80.5/80.7                          3.0/3.3                            67.8/68.7                    14.4/14.1                          46.4/46.0                          NA                                          NA                                       NA                            30 d
  Rader et al,^[@zoi190207r18]^ 2010       RC             CABG/VS         Preoperative RASIs         3437/3437                                               66/66                              72.4/74.8                          Excluded                           86/70                        45/30                              NA                                 68/66                                       NA                                       39/18                         In hospital
  Yoo et al,^[@zoi190207r19]^ 2010         RC             CABG            Preoperative RASIs         296/176                                                 65/65                              63.9/56.8                          NA                                 68.6/61.4                    43.6/31.8                          NA                                 69.3/64.8                                   51/46                                    NA                            30 d
  El-Haddad et al,^[@zoi190207r20]^ 2011   RCT            CABG            Preoperative ARB           50/50                                                   58.7/60.0                          58/52                              Excluded                           80/88                        58/52                              NA                                 82/82                                       60/62                                    NA                            In hospital
  Radaelli et al,^[@zoi190207r21]^ 2011    RC             CABG            Preoperative RASIs         1635/1504                                               61.2/61.6                          64.2/68.9                          4.1/2.8                            83.2/60.9                    34.3/24.5                          46.9/36.2                          NA                                          NA                                       46.9/36.2                     In hospital
  Barodka et al,^[@zoi190207r22]^ 2011     RC             CABG/VS         Preoperative RASIs         122/224                                                 73.8/74.5                          71/62                              NA                                 90.2/75.9                    32.8/27.2                          NA                                 81.2/74.6                                   73.3/70.2                                14.8/8.0                      30 d
  Bandeali et al,^[@zoi190207r23]^ 2012    RC             CABG            Preoperative ACEI          3983/4906                                               64.2/63.6                          74.2/76.4                          6.7/7.1                            93.7/76.5                    49.3/33.1                          42.2/39.7                          59.0/50.8                                   71.9/57.9                                NA                            In hospital
  Chin et al,^[@zoi190207r24]^ 2012        RC             CABG            Preoperative RASIs         407/643                                                 64/65                              74.7/75.3                          Excluded                           74.2/56.1                    53.8/41.7                          20.9/15.9                          63.6/59.6                                   65.8/58.3                                2.9/1.6                       In hospital
  Pretorius et al,^[@zoi190207r25]^ 2012   RCT            CABG/VS         Preoperative RASIs         298/147                                                 58.9/60.0                          67.7/64.0                          Excluded                           61.1/66.0                    22.1/20.4                          NA                                 50.3/49.0                                   53.0/57.1                                NA                            In hospital

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; CHF, congestive heart failure; EH, essential hypertension; MI, myocardial infarction; NA, not available; PC, prospective controlled; RASI, renin-angiotensin system inhibitor; RC, retrospective controlled; RCT, randomized clinical trial; VS, valvular surgery.

Primary Outcome for RASIs and POAF {#H2-6-ZOI190207}
----------------------------------

All included studies reported POAF events. A total of 13 553 participants were allocated to the RASI group and 14 332 to the control group. As demonstrated in [Figure 1](#zoi190207f1){ref-type="fig"}A, the incidence of POAF was 3542 (26.1%) in the RASI group and 3476 (24.3%) in the control group. Use of RASIs was not associated with reduced risk of POAF (OR, 1.04; 95% CI, 0.91-1.19; *P* = .55; *z* = 0.60, random-effects model). A notable between-study heterogeneity was observed in this comparison (*I*^2^ = 72%).

![Pooled Analysis for the Comparison of the Risk for Postoperative Atrial Fibrillation (POAF)\
M-H indicates Mantel-Haenszel; OR, odds ratio; and RASI, renin-angiotensin system inhibitor.](jamanetwopen-2-e194934-g001){#zoi190207f1}

Meta-Analysis Focusing on Randomized Trials {#H2-7-ZOI190207}
-------------------------------------------

Three randomized clinical trials (RCTs) were included in the systematic review.^[@zoi190207r16],[@zoi190207r20],[@zoi190207r25]^ Pooled analysis of these RCTs did not show a significant association of RASI use over the control group with POAF (OR, 0.43; 95% CI, 0.14-1.28; *P* = .13; *z* = 1.52, with random-effects model) ([Figure 1](#zoi190207f1){ref-type="fig"}B).

Sensitivity Analysis and Subgroup Analyses {#H2-8-ZOI190207}
------------------------------------------

Results of the Begg (τ = −0.47; *z* = 2.02; *P* = .04) and Egger (intercept, −1.66 \[SE, 0.79\]; *t* = 2.08; *P* = .07) tests showed a moderate risk of publication bias. Sensitivity analysis further demonstrated a good stability of the overall effect (eFigure 2 in the [Supplement](#note-ZOI190207-1-s){ref-type="supplementary-material"}). As shown in [Table 2](#zoi190207t2){ref-type="table"}, subgroup analyses showed consistent results based on study types (OR for RCTs only, 0.43; 95% CI, 0.14-1.28; *P* = .13), study settings (OR for CABG setting only, 1.12 \[95% CI, 0.95-1.33; *P* = .18\]; OR for CABG and valvular surgery setting, 0.88 \[95% CI, 0.67-1.17; *P* = .39\]), sample size (OR for studies with \>100 patients each group, 1.10; 95% CI, 0.98-1.22; *P* = .11), new-onset AF (OR, 0.87; 95% CI, 0.59-1.26; *P* = .44), and follow-up period (OR for in-hospital POAF, 1.02 \[95% CI, 0.86-1.20; *P* = .84\]; OR for 30-day POAF, 1.06 \[95% CI, 0.80-1.41; *P* = .69\]).

###### Subgroup Analyses for Effect of RASIs on POAF (RASI vs Control Groups)

  Subgroups Based on Study Characteristics   No. of Studies Included   Incidence of POAF, RASI/Control Groups, %   OR (95% CI)        *z* Effect   *P* Value
  ------------------------------------------ ------------------------- ------------------------------------------- ------------------ ------------ -----------
  Only RCTs included                         3                         21.1/26.8                                   0.43 (0.14-1.28)   1.52         .13
  Only CABG setting                          6                         24.5/21.8                                   1.12 (0.95-1.33)   1.34         .18
  CABG and VS setting                        5                         29.9/30.1                                   0.88 (0.67-1.17)   0.87         .39
  \>100 Patients each group                  9                         26.3/24.2                                   1.10 (0.98-1.22)   1.62         .11
  New-onset AF                               5                         27.8/26.6                                   0.87 (0.59-1.26)   0.47         .44
  In-hospital POAF                           7                         26.2/24.7                                   1.02 (0.86-1.20)   0.20         .84
  30-d POAF                                  4                         25.9/22.9                                   1.06 (0.80-1.41)   0.41         .69
  Use of β-blockers \>80%                    4                         20.1/32.9                                   0.40 (0.17-0.94)   −2.11        .04
  Participants \>70% male                    6                         26.9/23.9                                   1.15 (1.01-1.32)   2.13         .03

Abbreviations: AF, atrial fibrillation; CABG, coronary artery bypass graft; OR, odds ratio; POAF, postoperative atrial fibrillation; RASI, renin-angiotensin system inhibitor; RCT, randomized clinical trial; VS, valvular surgery.

Metaregression Analysis {#H2-9-ZOI190207}
-----------------------

The results of regression analysis are demonstrated in [Table 3](#zoi190207t3){ref-type="table"}. Known baseline variables for regression analysis included sample size, age, sex, history of AF, hypertension, diabetes, previous myocardial infarction, heart failure, use of a β-blocker, and use of statins. Male sex was significantly associated with an increased risk of POAF (τ^2^ = 0.0065; *z* = 3.47; *Q* = 12.047; *P* \< .001), and use of β-blockers was significantly associated with a reduced risk of POAF (τ^2^ = 0.018; *z* = −2.24; *Q* = 5.0091; *P* = .03) ([Figure 2](#zoi190207f2){ref-type="fig"}).

###### Metaregression Analyses

  Covariates    No. of Observations   τ^2^ Value   *z* Value for Slope   *Q* Value   *P* Value   Significance With the Logarithm OR
  ------------- --------------------- ------------ --------------------- ----------- ----------- ------------------------------------
  Sample size   11                    0.026        1.66                  2.75        .10         No
  Age           11                    0.027        1.40                  1.97        .16         No
  Male sex      11                    0.0065       3.47                  12.047      \<.001      Significant
  Prior AF      4                     0.072        0.064                 0.0041      .95         No
  EH            11                    0.035        0.068                 0.0047      .95         No
  Diabetes      11                    0.032        −0.82                 0.67        .41         No
  Prior MI      5                     0.028        −0.84                 0.71        .40         No
  CHF           6                     0.039        −0.059                0.0035      .95         No
  β-Blockers    9                     0.018        −2.24                 5.0091      .03         Significant
  Statins       7                     0.042        0.20                  0.041       .84         No

Abbreviations: AF, atrial fibrillation; CHF, congestive heart failure; EH, essential hypertension; MI, myocardial infarction; OR, odds ratio.

![Regression Analyses of Male Sex and Use of β-Blockers Against Logarithm Odds Ratio (OR)\
Circles indicate the individual study included in the regression analysis; different sizes indicate the sample size of the individual study.](jamanetwopen-2-e194934-g002){#zoi190207f2}

Secondary Outcomes of Stroke and Mortality, and Composite Outcome of Adverse Cardiac Events {#H2-10-ZOI190207}
-------------------------------------------------------------------------------------------

Five trials with 22 658 patients reported postoperative stroke events.^[@zoi190207r17],[@zoi190207r18],[@zoi190207r22],[@zoi190207r23],[@zoi190207r25]^ Meta-analysis showed a similar incidence of stroke in the RASI and control groups (1.8% vs 2.0%; OR, 0.86; 95% CI, 0.62-1.19; *P* = .37; *z* = 0.90; without significant heterogeneity, *P* = .11) (eFigure 3 in the [Supplement](#note-ZOI190207-1-s){ref-type="supplementary-material"}). Seven studies with a total of 26 269 patients reported data for all-cause mortality.^[@zoi190207r17],[@zoi190207r18],[@zoi190207r19],[@zoi190207r21],[@zoi190207r22],[@zoi190207r23],[@zoi190207r25]^ The pooled result showed no significant difference regarding the mortality rate between the RASI and control groups (3.2% vs 3.2%; OR, 1.07; 95% CI, 0.85-1.35; *P* = .56; *z* = 0.59; without significant heterogeneity, *P* = .12) (eFigure 3 in the [Supplement](#note-ZOI190207-1-s){ref-type="supplementary-material"}). Further meta-analysis for a composite outcome of adverse cardiac events showed similar rates of events between the RASI and control groups (30.6% vs 28.9%; OR, 1.04; 95% CI, 0.91-1.18; *P* = .58; *z* = 0.56) (eFigure 3 in the [Supplement](#note-ZOI190207-1-s){ref-type="supplementary-material"}).

Hospitalization {#H2-11-ZOI190207}
---------------

Four studies reported the outcome data of hospitalization.^[@zoi190207r19],[@zoi190207r20],[@zoi190207r22],[@zoi190207r25]^ Pooled analysis of this outcome showed a similar duration of hospital stay between the RASI and control groups (weighted mean difference, −0.04; 95% CI, −1.05 to 0.98; *P* = .94; *z* = 0.07) (eFigure 4 in the [Supplement](#note-ZOI190207-1-s){ref-type="supplementary-material"}).

Discussion {#H1-4-ZOI190207}
==========

Main Findings {#H2-12-ZOI190207}
-------------

In this study, we compared the rate of POAF and adverse events in patients undergoing cardiac surgery who received preoperative RASI treatment vs a control group of patients undergoing cardiac surgery who did not receive RASI treatment. The results demonstrated a nonsignificant association of preoperative RASIs in reducing the risk of POAF; moreover, preoperative RASI treatment was not associated with a reduced rate of postoperative stroke, shortened hospitalization, or decreased perioperative mortality.

Mechanism of Postoperative AF and Potential Role of RASIs in AF {#H2-13-ZOI190207}
---------------------------------------------------------------

POAF is a well-known clinical complication, and it occurs in approximately one-third of patients undergoing cardiac surgery.^[@zoi190207r26]^ Despite remarkable development in medical care and technology during the last few decades, the incidence of POAF remains unsatisfactorily high, leading to significantly increased morbidity, health care costs, and even mortality.^[@zoi190207r1],[@zoi190207r2],[@zoi190207r3],[@zoi190207r4],[@zoi190207r5],[@zoi190207r6],[@zoi190207r7],[@zoi190207r8]^ In our pooled data including 27 885 patients who underwent cardiac surgery, 7018 (25.2%) developed POAF, suggesting an urgent need for a therapeutic approach to treat this postoperative complication.

The specific mechanism underlying POAF remains to be fully elucidated. Structural and electrical remodeling has been proposed to be associated with the pathogenesis of POAF.^[@zoi190207r26]^ Perioperative cardiac injuries and structural cardiac diseases (ie, atrial dilation and atrial fibrosis) are important elements of cardiac structural remodeling that can result in diverse electrical conduction properties and therefore configure new reentry foci. Pathophysiologically, ischemic myocardial damage, inflammatory response, and disturbance of autonomic tone contribute to cardiac electrical remodeling, and all these factors play a pivotal role in the initiation and maintenance of POAF.^[@zoi190207r26]^ The development of POAF seems multifactorial. Clinical factors such as advanced age, male sex, history of AF, hypertension, diabetes, and decreased left ventricular function have all been identified as risk factors for POAF.^[@zoi190207r6],[@zoi190207r9],[@zoi190207r27]^ Cumulative data from clinical studies suggests that RASIs play a protective role to prevent AF in selected patients owing to their upstream regulation and antiremodeling effect.^[@zoi190207r28],[@zoi190207r29]^ However, these studies mainly focused on patients in the nonsurgical setting.

Interpretation of Previous Trials and Results {#H2-14-ZOI190207}
---------------------------------------------

Among the included studies, only 2^[@zoi190207r16],[@zoi190207r20]^ showed favorable outcomes in patients undergoing preoperative RASI therapy. Although the randomized method was applied, the statistical power of these 2 studies was largely restricted by the small sample size. At the same time, 2 large-scale observational studies^[@zoi190207r17],[@zoi190207r23]^ demonstrated a significantly higher risk of major cardiac adverse events, including POAF, among patients who received preoperative RASI treatment.

The study by Pretorius and colleagues^[@zoi190207r25]^ is, to date and to our knowledge, the largest RCT on this topic. Four hundred forty-five patients scheduled for cardiac surgery were randomized into treatment with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or placebo (control group). All patients were treated with conventional medical care guided by institutional protocol.^[@zoi190207r25]^ Blood tests for angiotensin-converting enzyme activity and aldosterone concentrations were performed after randomization. POAF was confirmed by continuous electrocardiographic monitoring throughout the postoperative period until discharge. During in-hospital follow-up, no statistical difference was found among the 3 groups regarding the incidence of POAF.^[@zoi190207r25]^

Conventional Management for POAF {#H2-15-ZOI190207}
--------------------------------

At present, pharmacotherapy is the primary preventive method to reduce the incidence of POAF. The most widely used medication is β-blockers. A recent meta-analysis of 2556 patients undergoing cardiac surgery^[@zoi190207r30]^ demonstrated a significantly reduced risk of POAF associated with β-blocker therapy. This finding seems to be in line with our regression analysis results, which suggest that β-blockers play a protective role in reducing POAF. Current international guidelines recommend that in the absence of contraindications, β-blockers should be given to patients scheduled to undergo cardiac surgery (class I, level A).^[@zoi190207r31],[@zoi190207r32]^ Regarding class III antiarrhythmic drugs, amiodarone hydrochloride and sotalol hydrochloride were shown to significantly decrease the incidence of POAF; however, owing to their potential adverse effects such as bradycardia, hypotension, and ventricular arrhythmias, particularly in patients with electrolyte disturbance, such drugs should be used with caution.^[@zoi190207r31],[@zoi190207r33]^ In addition, nonantiarrhythmic drugs targeting the atrial substrate and inflammation process are of interest. Statins are well known to lower lipid levels, and they have also been shown to exert a variety of protective effects such as anti-inflammation, antioxidation, and regulation of endothelial function. Previous large-sample meta-analyses found a substantially reduced risk of POAF, stroke, and mortality associated with statin therapy in patients undergoing cardiac surgery.^[@zoi190207r34],[@zoi190207r35]^

Polyunsaturated ω-3 fatty acids participate in the stabilizing of biological membrane and are known to mitigate inflammation and oxidative stress and to potentially prevent remodeling. However, a major RCT^[@zoi190207r36]^ and a meta-analysis^[@zoi190207r37]^ failed to exhibit additional benefit of polyunsaturated ω-3 fatty acids in reducing the risk of POAF.

Corticosteroids exert potent anti-inflammation effects. A previous meta-analysis^[@zoi190207r38]^ showed that corticosteroid treatment was associated with a significant reduction in POAF. However, given the potential adverse effects on glucose metabolism, wound healing, and infection, conventional use of corticosteroids for POAF prevention remains controversial.

Colchicine has also been shown to suppress chemotactic factor, attenuate neutrophil activation, and modulate endothelial cell adhesion and migration to injured tissues.^[@zoi190207r39]^ In 2014, the Colchicine for Prevention of the Postpericardiotomy Syndrome and Postoperative Atrial Fibrillation (COPPS-2) trial^[@zoi190207r40]^ showed that preoperative colchicine treatment was associated with decreased risk of postpericardiotomy syndrome, but no association was found with incidence of POAF.

Significance of the Present Study {#H2-16-ZOI190207}
---------------------------------

Pooled analyses using data from relevant clinical studies are increasingly used in evidence-based medicine, and clinical evidence of high quality can be provided if potential bias is properly controlled for. In the present study, we conducted a predefined literature search, including 27 885 patients from 11 published studies, most of which were of medium to high methodological quality. We predefined the primary outcome as the rate of POAF, and our results showed that preoperative RASI therapy was not associated with additional clinical benefit in the setting of cardiac surgery. Despite notable heterogeneity among the included studies, further evaluation by sensitivity analysis and comprehensive subgroup and meta-regression analyses did not show fundamental shifting of the overall effect, indicating a good stability of the primary result.

Consistent with the primary outcome, the analysis of secondary end points, including the risk of postoperative stroke, death, composite cardiac adverse events, and hospitalization, also revealed neutral results. These findings suggest that preoperative RASI therapy may not confer an additional protective effect for POAF prevention. Moreover, the metaregression analysis showed that male sex is a significant risk factor for POAF, and the use of β-blockers was associated with a significantly reduced risk in developing POAF.

Limitations {#H2-17-ZOI190207}
-----------

Although methodological efforts have been made to control for potential bias, limitations of the present study should be noted. This study was a meta-analysis of aggregate data rather than an individual patient-level study. One major limitation of the present study is a lack of RCTs. Most of the included trials were retrospective in nature; despite comprehensive subgroup analyses and regression analyses, the influence of unreported confounding factors cannot be fully ruled out. Limited data were available regarding the specific types and doses of RASIs prescribed, making it very difficult, if not impossible, to distinguish the drug-class effect and the dose effect in our analysis.

Conclusions {#H1-5-ZOI190207}
===========

This large-sample pooled analysis involving existing evidence suggests that preoperative treatment using RASIs does not appear to offer additional benefit in reducing the acute risk of POAF, stroke, mortality, and hospitalization in the setting of cardiac surgery. Male sex was found to be associated with an increased risk of developing POAF, and the use of β-blockers was associated with a significantly reduced risk of developing POAF.
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